Brodalumab: an Evidence-based Review of Its Potential in the Treatment of Moderate-to-severe Psoriasis

Overview

Journal Core Evid

Publisher Dove Medical Press

Specialty Pharmacology

Date 2014 Aug 6

PMID 25093016

Citations 8

Authors

Susana Coimbra

Americo Figueiredo

Alice Santos-Silva

Affiliations

Soon will be listed here.

Abstract

Advances in knowledge regarding the pathogenesis of psoriasis have allowed the development of a new class of agents known as biologic drugs. Data confirm that T helper (Th)17 and interleukin (IL)-17 signaling has a crucial role in the pathogenesis of the disease. High levels of IL-17 and Th17-related cytokines have been reported in psoriasis, leading to the suggestion of agents targeting IL-17 as a potential therapeutic strategy in psoriasis. Brodalumab is a human monoclonal antibody that targets IL-17 receptor A, blocking the effects of IL-17A, IL-17F, and IL-17E. Data from Phase I and Phase II clinical trials indicate that brodalumab has a favorable safety and tolerability profile, with strong clinical activity, suggesting that it is a potential tool for use in the treatment of moderate-to-severe psoriasis.

Citing Articles

Management of Moderate to Severe Plaque Psoriasis with Brodalumab in Daily Practice: Real-World Evidence from the LIBERO Study in the Czech Republic.

Gkalpakiotis S, Kojanova M, Fialova J, Cetkovska P, Vasku V, Vantuchova Y Dermatol Ther (Heidelb). 2023; 14(1):115-130.

PMID: 38032433 PMC: 10828329. DOI: 10.1007/s13555-023-01066-z.

New insights into the function of Interleukin-25 in disease pathogenesis.

Yuan Q, Peng N, Xiao F, Shi X, Zhu B, Rui K Biomark Res. 2023; 11(1):36.

PMID: 37005677 PMC: 10068183. DOI: 10.1186/s40364-023-00474-9.

Effect of γ-secretase inhibitor on Th17 cell differentiation and function of mouse psoriasis-like skin inflammation.

Ma L, Xue H, Qi R, Wang Y, Yuan L J Transl Med. 2018; 16(1):59.

PMID: 29523162 PMC: 5845192. DOI: 10.1186/s12967-018-1442-6.

Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy.

Roman M, Chiu M Drug Des Devel Ther. 2017; 11:2065-2075.

PMID: 28744098 PMC: 5511025. DOI: 10.2147/DDDT.S113683.

Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis.

Attia A, Abushouk A, Ahmed H, Gadelkarim M, Elgebaly A, Hassan Z Clin Drug Investig. 2017; 37(5):439-451.

PMID: 28197901 DOI: 10.1007/s40261-017-0500-9.

References

Bohm B, Burkhardt H, Uebe S, Apel M, Behrens F, Reis A . Identification of low-frequency TRAF3IP2 coding variants in psoriatic arthritis patients and functional characterization. Arthritis Res Ther. 2012; 14(2):R84. PMC: 3446458. DOI: 10.1186/ar3807. View

Naldi L, Gambini D . The clinical spectrum of psoriasis. Clin Dermatol. 2007; 25(6):510-8. DOI: 10.1016/j.clindermatol.2007.08.003. View

Hvid H, Teige I, Kvist P, Svensson L, Kemp K . TPA induction leads to a Th17-like response in transgenic K14/VEGF mice: a novel in vivo screening model of psoriasis. Int Immunol. 2008; 20(8):1097-106. DOI: 10.1093/intimm/dxn068. View

Korn T, Bettelli E, Oukka M, Kuchroo V . IL-17 and Th17 Cells. Annu Rev Immunol. 2009; 27:485-517. DOI: 10.1146/annurev.immunol.021908.132710. View

He D, Wu L, Kim H, Li H, Elmets C, Xu H . CD8+ IL-17-producing T cells are important in effector functions for the elicitation of contact hypersensitivity responses. J Immunol. 2006; 177(10):6852-8. PMC: 3179908. DOI: 10.4049/jimmunol.177.10.6852. View

Numasaki M, Lotze M, Sasaki H . Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts. Immunol Lett. 2004; 93(1):39-43. DOI: 10.1016/j.imlet.2004.01.014. View

Puel A, Cypowyj S, Bustamante J, Wright J, Liu L, Lim H . Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011; 332(6025):65-8. PMC: 3070042. DOI: 10.1126/science.1200439. View

van der Fits L, Mourits S, Voerman J, Kant M, Boon L, Laman J . Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2009; 182(9):5836-45. DOI: 10.4049/jimmunol.0802999. View

Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A . Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-α levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy. Br J Dermatol. 2010; 163(6):1282-90. DOI: 10.1111/j.1365-2133.2010.09992.x. View

10.

Zaba L, Suarez-Farinas M, Fuentes-Duculan J, Nograles K, Guttman-Yassky E, Cardinale I . Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol. 2009; 124(5):1022-10.e1-395. PMC: 2852188. DOI: 10.1016/j.jaci.2009.08.046. View

11.

Papp K, Leonardi C, Menter A, Ortonne J, Krueger J, Kricorian G . Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012; 366(13):1181-9. DOI: 10.1056/NEJMoa1109017. View

12.

Shi X, Jin L, Dang E, Chang T, Feng Z, Liu Y . IL-17A upregulates keratin 17 expression in keratinocytes through STAT1- and STAT3-dependent mechanisms. J Invest Dermatol. 2011; 131(12):2401-8. DOI: 10.1038/jid.2011.222. View

13.

Onishi R, Gaffen S . Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology. 2010; 129(3):311-21. PMC: 2826676. DOI: 10.1111/j.1365-2567.2009.03240.x. View

14.

Gottlieb S, Gilleaudeau P, Johnson R, Estes L, Woodworth T, Gottlieb A . Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995; 1(5):442-7. DOI: 10.1038/nm0595-442. View

15.

Pietrzak A, Zalewska A, Chodorowska G, Krasowska D, Michalak-Stoma A, Nockowski P . Cytokines and anticytokines in psoriasis. Clin Chim Acta. 2008; 394(1-2):7-21. DOI: 10.1016/j.cca.2008.04.005. View

16.

Liu S, Tsai J, Shen C, Sher Y, Hsieh C, Yeh Y . Induction of a distinct CD8 Tnc17 subset by transforming growth factor-beta and interleukin-6. J Leukoc Biol. 2007; 82(2):354-60. DOI: 10.1189/jlb.0207111. View

17.

Szegedi A, Aleksza M, Gonda A, Irinyi B, Sipka S, Hunyadi J . Elevated rate of Thelper1 (T(H)1) lymphocytes and serum IFN-gamma levels in psoriatic patients. Immunol Lett. 2003; 86(3):277-80. DOI: 10.1016/s0165-2478(03)00025-7. View

18.

Nair R, Callis Duffin K, Helms C, Ding J, Stuart P, Goldgar D . Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet. 2009; 41(2):199-204. PMC: 2745122. DOI: 10.1038/ng.311. View

19.

Miossec P, Korn T, Kuchroo V . Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009; 361(9):888-98. DOI: 10.1056/NEJMra0707449. View

20.

Ortega C, Fernandez-A S, Carrillo J, Romero P, Molina I, Moreno J . IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol. 2009; 86(2):435-43. DOI: 10.1189/JLB.0109046. View